Danny Beales MP: written questions
189 published records · newest first.
Written questions
Social Rented Housing: FurnitureMinistry of Housing, Communities and Local GovernmentTabled 25 Nov 2025AnsweredUIN 94603More
Question: To ask the Secretary of State for Housing, Communities and Local Government, what assessment he has made of the potential impact of furniture provision on (a) tenancy sustainability and (b) homelessness; and if his Department will encourage local authorit
Answer: I refer the hon. Member to the answer given to question UIN 92799 on 28 November 2025.
Answered 3 Dec 2025
Original Parliament recordFireworks: RegulationDepartment for Business and TradeTabled 19 Nov 2025AnsweredUIN 92665More
Question: To ask the Secretary of State for Business and Trade, whether his Department plans to conduct a review into current fireworks legislation to determine whether it is fit for purpose and efficiently protects animals and vulnerable people.
Answer: The Government is continuing to engage with businesses, consumer groups and charities, including those supporting animals and vulnerable people, to gather evidence on the issues with and impacts of fireworks to inform any future action and review into the...
Answered 1 Dec 2025
Original Parliament recordNoise: Pollution ControlDepartment for Business and TradeTabled 19 Nov 2025AnsweredUIN 92664More
Question: To ask the Secretary of State for Business and Trade, what assessment his Department has made of the adequacy of the 120 dB noise limit in protecting animals and vulnerable people from harm.
Answer: The Government is continuing to engage with businesses, consumer groups and charities, including those supporting animals and vulnerable people, to gather evidence on the issues with and impacts of fireworks to inform any future action and review into the...
Answered 1 Dec 2025
Original Parliament recordSocial Rented Housing: FurnitureMinistry of Housing, Communities and Local GovernmentTabled 21 Oct 2025AnsweredUIN 84059More
Question: To ask the Secretary of State for Housing, Communities and Local Government, whether his Department plans to write to social landlords to encourage them to offer a proportion of their properties as furnished, in the context of the best practice guide with
Answer: My Department engages actively with registered providers of social housing on all issues facing social housing tenants and with a range of stakeholders on issues facing residents and has engaged with groups such as End Furniture Poverty to understand thei...
Answered 3 Nov 2025
Original Parliament recordRented Housing: FurnitureMinistry of Housing, Communities and Local GovernmentTabled 21 Oct 2025AnsweredUIN 84058More
Question: To ask the Secretary of State for Housing, Communities and Local Government, if he will make an assessment of the potential impact of the best practice guide within the Decent Homes Standard on the number of landlords who furnish their properties using fu
Answer: My Department engages actively with registered providers of social housing on all issues facing social housing tenants and with a range of stakeholders on issues facing residents and has engaged with groups such as End Furniture Poverty to understand thei...
Answered 3 Nov 2025
Original Parliament recordRented Housing: StandardsMinistry of Housing, Communities and Local GovernmentTabled 21 Oct 2025AnsweredUIN 84056More
Question: To ask the Secretary of State for Housing, Communities and Local Government, what steps his Department plans to take to help ensure that landlords (a) introduce flooring in all habitable rooms within a reasonable timeframe and (b) otherwise follow the Dec
Answer: My Department engages actively with registered providers of social housing on all issues facing social housing tenants and with a range of stakeholders on issues facing residents and has engaged with groups such as End Furniture Poverty to understand thei...
Answered 3 Nov 2025
Original Parliament recordFurniture PovertyMinistry of Housing, Communities and Local GovernmentTabled 21 Oct 2025AnsweredUIN 84055More
Question: To ask the Secretary of State for Housing, Communities and Local Government, what estimate his Department has made of the level of furniture poverty in Uxbridge and South Ruislip constituency; and if he will make an assessment of the potential impact of f
Answer: My Department engages actively with registered providers of social housing on all issues facing social housing tenants and with a range of stakeholders on issues facing residents and has engaged with groups such as End Furniture Poverty to understand thei...
Answered 3 Nov 2025
Original Parliament recordHousing: StandardsMinistry of Housing, Communities and Local GovernmentTabled 21 Oct 2025AnsweredUIN 84054More
Question: To ask the Secretary of State for Housing, Communities and Local Government, what steps his Department plans to take to monitor the implementation of the Decent Homes Standard in relation to (a) the best practice guide and (b) furniture provision within s
Answer: My Department engages actively with registered providers of social housing on all issues facing social housing tenants and with a range of stakeholders on issues facing residents and has engaged with groups such as End Furniture Poverty to understand thei...
Answered 3 Nov 2025
Original Parliament recordAbirateroneDepartment of Health and Social CareTabled 17 Oct 2025AnsweredUIN 83210More
Question: To ask the Secretary of State for Health and Social Care, whether the NICE guidance on abiraterone produced in 2021 was based on abiraterone's cost in generic form.
Answer: The National Institute for Health and Care Excellence’s (NICE) published guidance on abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer, which has the reference code TA721, was developed before the patent for a...
Answered 24 Oct 2025
Original Parliament recordAbirateroneDepartment of Health and Social CareTabled 17 Oct 2025AnsweredUIN 83209More
Question: To ask the Secretary of State for Health and Social Care, for what reason NHS England has not approved abiraterone for use in high-risk, non-metastatic prostate cancer.
Answer: Abiraterone is licensed by the Medicines and Healthcare products Regulatory Agency for use in the treatment of high-risk hormone-sensitive metastatic prostate cancer. The National Institute for Health and Care Excellence (NICE) has published final draft g...
Answered 26 Nov 2025
Original Parliament recordAbirateroneDepartment of Health and Social CareTabled 17 Oct 2025AnsweredUIN 83208More
Question: To ask the Secretary of State for Health and Social Care, what information his Department holds on the estimate made by (a) NHS England, (b) NHS Wales and (c) NHS Scotland of the incremental cost-effectiveness ratio for abiraterone in high-risk, non-metas
Answer: NHS England has not calculated the incremental cost-effectiveness ratio for any policy proposition because NHS England uses a relative prioritisation process for policy propositions that require funding in line with the published NHS England Specialised C...
Answered 28 Oct 2025
Original Parliament recordAbirateroneDepartment of Health and Social CareTabled 17 Oct 2025AnsweredUIN 83207More
Question: To ask the Secretary of State for Health and Social Care, whether NHS England has approved any drugs with a higher incremental cost-effectiveness ratio than abiraterone for high-risk, non-metastatic prostate cancer in the last five years.
Answer: NHS England has not calculated the incremental cost-effectiveness ratio for any policy proposition because NHS England uses a relative prioritisation process for policy propositions that require funding in line with the published NHS England Specialised C...
Answered 28 Oct 2025
Original Parliament recordProstate Cancer: AbirateroneDepartment of Health and Social CareTabled 17 Oct 2025AnsweredUIN 83206More
Question: To ask the Secretary of State for Health and Social Care, if he will make an estimate of the (a) cost per patient, (b) number of eligible patients, (c) net cost, (d) incremental quality-adjusted life years gained and (e) incremental cost-effectiveness rat
Answer: NHS England is unable to provide information related to the cost per patient as disclosure of this information could be used to identify the discounted price that we have agreed and would prejudice the commercial interests of both NHS England and the supp...
Answered 28 Oct 2025
Original Parliament recordAbirateroneDepartment of Health and Social CareTabled 17 Oct 2025AnsweredUIN 83205More
Question: To ask the Secretary of State for Health and Social Care, if he will make an estimate of the potential impact of prescribing abiraterone in England using the eligibility criteria used in (a) Scotland and (b) Wales on the number of premature deaths from hi
Answer: NHS England estimates that the number of eligible patients in England is between 7,500 and 9,500 per year. This is based on the same eligibility criteria as are used in Scotland and Wales. NHS England has not completed any specific work to estimate the po...
Answered 28 Oct 2025
Original Parliament recordAbirateroneDepartment of Health and Social CareTabled 17 Oct 2025AnsweredUIN 83204More
Question: To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of men in England with newly diagnosed high-risk, non-metastatic prostate cancer who would be eligible for abiraterone under the eligibility crit
Answer: NHS England estimates that the number of eligible patients in England is between 7,500 and 9,500 per year. This is based on the same eligibility criteria as are used in Scotland and Wales. NHS England has not completed any specific work to estimate the po...
Answered 28 Oct 2025
Original Parliament recordRare Cancers: Medical TreatmentsDepartment of Health and Social CareTabled 14 Oct 2025AnsweredUIN 82215More
Question: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of minimally invasive therapies for the less survivable cancers.
Answer: Ongoing research is exploring the potential of minimally invasive cancer therapies for less survivable cancers. This includes non-invasive liver cancer treatments that use ultrasound technology to destroy tumours without surgery, scalpels, or radiation, w...
Answered 28 Oct 2025
Original Parliament recordRare Cancers: DiagnosisDepartment of Health and Social CareTabled 14 Oct 2025AnsweredUIN 82214More
Question: To ask the Secretary of State for Health and Social Care, how the full roll-out of the non-specific symptom pathways is being measured; and how their development has included the less survivable cancers.
Answer: Since 2019, NHS England and cancer alliances have been developing non-specific symptom (NSS) pathways for patients who present with vague and non-site-specific symptoms which do not clearly align to a tumour type. Full roll out of NSS pathways has been ac...
Answered 23 Oct 2025
Original Parliament recordMedical TreatmentsDepartment of Health and Social CareTabled 10 Oct 2025AnsweredUIN 80991More
Question: To ask the Secretary of State for Health and Social Care, whether there is a facility for the NHS to approve treatments without external payment for assessment by the National Institute for Health and Care Excellence.
Answer: The National Institute for Health and Care Excellence (NICE) charges companies for the development of its technology appraisal and highly specialised technologies recommendations on medicines and other health technologies. Where a company does not partici...
Answered 15 Oct 2025
Original Parliament recordClinical Priorities Advisory GroupDepartment of Health and Social CareTabled 11 Sept 2025AnsweredUIN 76769More
Question: To ask the Secretary of State for Health and Social Care, whether the Clinical Priorities Advisory Group has a budget to approve new treatments.
Answer: The Clinical Priorities Advisory Group is an advisory committee that makes recommendations on the relative priority of treatments to be commissioned subject to the available discretionary investment. It is not a decision-making body and does not allocate ...
Answered 13 Oct 2025
Original Parliament recordProstate Cancer: Hormone TreatmentsDepartment of Health and Social CareTabled 1 Sept 2025AnsweredUIN 73656More
Question: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 July 2025 to Question 64681 on Prostate Cancer: Hormone Treatments, for what reason recurrent headroom in revenue budgets is considered a barrier to implementing the abi
Answer: Reimbursement of abiraterone across all indications is managed at a national level by NHS England who must ensure the affordability of introducing any new routine commissioning policies, alongside maintaining existing services for patients and meeting the...
Answered 19 Sept 2025
Original Parliament recordRadiotherapy: Medical EquipmentDepartment of Health and Social CareTabled 18 Jul 2025AnsweredUIN 69135More
Question: To ask the Secretary of State for Health and Social Care, if he will take steps to include policies on replacing older radiotherapy machines in the national cancer plan.
Answer: The National Cancer Plan will cover the entirety of the cancer pathway, from referral and diagnosis to treatment and ongoing care. Radiotherapy plays a crucial role in the care of many cancer patients, and we remain committed to continuing support for rad...
Answered 28 Jul 2025
Original Parliament recordRadiotherapyDepartment of Health and Social CareTabled 18 Jul 2025AnsweredUIN 69134More
Question: To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of establishing a national radiotherapy advisory group.
Answer: The Government recognises radiotherapy as a crucial part of cancer treatment, which is why we have invested £70 million in 28 new radiotherapy machines to ensure the most advanced radiotherapy treatment is available to patients when they need it.There are...
Answered 28 Jul 2025
Original Parliament recordProstate Cancer: Hormone TreatmentsDepartment of Health and Social CareTabled 16 Jul 2025AnsweredUIN 68687More
Question: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 15 July 2025 to Question 64682 on Prostate Cancer: Hormone Treatments, if his Department will publish the Equality and Health Inequalities Impact Assessment for abirateron
Answer: The Equality and Health Inequalities Impact Assessment for abiraterone acetate plus prednisone for hormone-sensitive non-metastatic prostate cancer can be found in the attached document.
Answered 23 Jul 2025
Original Parliament recordRenewable Energy: Public SectorDepartment for Energy Security and Net ZeroTabled 9 Jul 2025AnsweredUIN 905218More
Question: To ask the Secretary of State for Energy Security and Net Zero, what steps Great British Energy is taking to help public services use more renewable energy.
Answer: GBE’s first investment, together with government, included £180 million for around 200 schools and 200 hospitals in England to install solar power and complementary technology, cutting energy costs. Eleven school installations have already happened, enabl...
Answered 15 Jul 2025
Original Parliament recordInnovation: Beer and Public HousesDepartment of Health and Social CareTabled 9 Jul 2025AnsweredUIN 66478More
Question: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of innovation in the beer and pub sector with the (a) development and (b) availability of (i) no and (ii) low alcohol products on the aims of the
Answer: In Fit for the Future: 10 Year Health Plan for England, the Government has committed to tackling harmful levels of alcohol consumption through exploring options to standardise which products can describe themselves as alcohol free. One of the first steps ...
Answered 28 Jul 2025
Original Parliament record
Published records only — not a full account of an MP’s work. How we work →